Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts (ETNA)
Epstein-Barr Virus Infections
About this trial
This is an interventional treatment trial for Epstein-Barr Virus Infections focused on measuring Cytotoxic T Lymphocytes, bone marrow transplant, EBV+ lymphoproliferative disease
Eligibility Criteria
INCLUSION CRITERIA: All patients receiving a T cell depleted BMT from a mismatched family member or unrelated donor will be eligible for this protocol. In addition, patients receiving a matched sibling transplant or T replete transplant may be eligible if they are at high risk of developing EBV LPD because of their underlying disease (e.g Wiskott-Aldrich or Ataxia Telangiectasia) or have a past history of EBVLPD or other EBV associated malignancy. O2 saturation > 90% on room air EXCLUSION CRITERIA: - Exclusion criteria for BMT will be as detailed in the relevant protocol. Exclusion criteria at time of administration CTLs: Patients with GVHD of Grade II or greater. Patients with severe renal disease (i.e., creatinine clearance less than half normal for age). Patients with severe hepatic disease (bilirubin greater than twice normal, or SGOT greater than 3 x normal). Patients with a severe intercurrent infection. Patients with a life expectancy <6 weeks
Sites / Locations
- Houston Methodist Hospital
- Texas Children's Hospital
Arms of the Study
Arm 1
Experimental
EBV specific T cells
EBV specific T cells